Pacira BioSciences, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 3 | $0.62 | $0.62 | $0.62 |
| Q2 2024 | 2 | $0.70 | $0.70 | $0.70 |
| Q3 2024 | 3 | $0.69 | $0.71 | $0.70 |
| Q4 2024 | 8 | $0.73 | $0.87 | $0.78 |
| Q1 2025 | 3 | $0.59 | $0.67 | $0.64 |
| Q2 2025 | 2 | $0.62 | $0.78 | $0.71 |
| Q3 2025 | 2 | $0.59 | $0.74 | $0.68 |
| Q4 2025 | 2 | $0.63 | $0.79 | $0.73 |
Pacira BioSciences, Inc. Earnings Date And Information
Pacira BioSciences, Inc. last posted its earnings results on Wednesday, November 6th, 2024. The company reported $0.79 earnings per share for the quarter, topping analysts' consensus estimates of $0.72 by $0.07. The company had revenue of 168.57 M for the quarter and had revenue of 674.98 M for the year. Pacira BioSciences, Inc. has generated $1 earnings per share over the last year ($0.81 diluted earnings per share) and currently has a price-to-earnings ratio of -8.84. Pacira BioSciences, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, February 27th, 2025 based on prior year's report dates.
Pacira BioSciences, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/06/2024 | Q3 2024 | $0.72 | -$3.11 | -3.83 | $169.55 M | $168.57 M |
| 07/30/2024 | Q2 2024 | $0.73 | $0.41 | -0.32 | $173.70 M | $178.02 M |
| 05/07/2024 | Q1 2024 | $0.64 | $0.19 | -0.45 | $167.12 M | |
| 02/29/2024 | Q4 2023 | $0.89 | $0.54 | -0.35 | $181.24 M | |
| 11/02/2023 | Q3 2023 | $0.84 | $0.23 | -0.61 | $172.95 M | $163.93 M |
| 08/02/2023 | Q2 2023 | $0.81 | $0.56 | -0.25 | $174.85 M | $169.47 M |
| 05/03/2023 | Q1 2023 | $0.60 | -$0.43 | -1.03 | $160.34 M | |
| 02/28/2023 | Q4 2022 | $0.80 | -$0.22 | -1.02 | $171.96 M | |
| 11/03/2022 | Q3 2022 | $0.73 | -$0.02 | -0.75 | $168.33 M | $167.47 M |
| 08/03/2022 | Q2 2022 | $0.85 | $0.40 | -0.45 | $170.64 M | $169.41 M |
| 05/04/2022 | Q1 2022 | $0.74 | $0.15 | -0.59 | $157.99 M | |
| 02/28/2022 | Q4 2021 | -$0.12 | $159.19 M | |||
| 11/03/2021 | Q3 2021 | $0.66 | $0.40 | -0.26 | $129.42 M | $127.72 M |
| 08/03/2021 | Q2 2021 | $0.76 | $0.43 | -0.33 | $132.48 M | $135.59 M |
| 05/04/2021 | Q1 2021 | $0.59 | $0.24 | -0.35 | $119.03 M | |
| 02/26/2021 | Q4 2020 | $0.33 | $128.55 M | |||
| 10/29/2020 | Q3 2020 | $3.03 | $116.13 M | $117.48 M | ||
| 08/06/2020 | Q2 2020 | $0.16 | -$0.17 | -0.33 | $72.08 M | $75.51 M |
| 05/07/2020 | Q1 2020 | $0.32 | $0.19 | -0.13 | $105.68 M | |
| 02/20/2020 | Q4 2019 | -$0.12 | $122.42 M |
Pacira BioSciences, Inc. Earnings: Frequently Asked Questions
-
When is Pacira BioSciences, Inc.'s earnings date?
Pacira BioSciences, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, February 27th, 2025 based off last year's report dates.
-
Did Pacira BioSciences, Inc. beat their earnings estimates last quarter?
In the previous quarter, Pacira BioSciences, Inc. (:PCRX) reported $0.79 earnings per share (EPS) to beat the analysts' consensus estimate of $0.72 by $0.07.
-
How can I listen to Pacira BioSciences, Inc.'s earnings conference call?
The conference call for Pacira BioSciences, Inc.'s latest earnings report can be listened to online.
-
How can I read Pacira BioSciences, Inc.'s conference call transcript?
The conference call transcript for Pacira BioSciences, Inc.'s latest earnings report can be read online.
-
How much revenue does Pacira BioSciences, Inc. generate each year?
Pacira BioSciences, Inc. (:PCRX) has a recorded annual revenue of $674.98 M.
-
How much profit does Pacira BioSciences, Inc. generate each year?
Pacira BioSciences, Inc. (:PCRX) has a recorded net income of $674.98 M. Pacira BioSciences, Inc. has generated $0.91 earnings per share over the last four quarters.
-
What is Pacira BioSciences, Inc.'s price-to-earnings ratio?
Pacira BioSciences, Inc. (:PCRX) has a price-to-earnings ratio of -8.84 and price/earnings-to-growth ratio is 0.04.
